Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07138040 · ClinicalTrials.gov registry record · NA

Re-Engaging AYA Survivors in Cancer-Related Healthcare

A NA study of Cancer, sponsored by Children's Hospital of Philadelphia.

Recruiting
Registry status
NA
Development phase
530
Enrollment target
3
Study locations

NCT07138040: Recruiting NA study of Cancer, sponsored by Children's Hospital of Philadelphia.

NCT07138040 is a NA study of Cancer that is actively recruiting participants, run by Children's Hospital of Philadelphia. The registered enrollment target is 530 participants, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (85% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07138040, a NA study of Cancer, is actively recruiting participants, sponsored by Children's Hospital of Philadelphia.

RECRUITING
Registry status
NA
Development phase
530 participants
Enrollment target
3
Study locations

Study Summary

The goal of this clinical trial is to test the efficacy (how well they work) of different digital interventions that deliver information to adolescent and young adult (AYA) survivors of childhood cancer to promote re-engagement in cancer-related long-term follow-up care (LTFU). The main aims are: * To test the efficacy of adaptive interventions (AIs) that begin with low touch intervention (LTI) as compared to written information (WI) on attending an appointment, and self-reported self-management among AYA. * To identify the most efficacious second-stage strategy for those who initially schedule/attend an appointment (maintenance vs. step-up) and for those who do not (step-up vs. step-up maximum). * To assess multilevel factors contributing to the effects of re-engaging AYA and how best to integrate AIs into practice. Throughout the duration of the study, participants will complete four surveys, receive a series of interventions, and may be asked to participate in an interview (post-intervention).

Primary Outcome

Percentage of participants who re-engage in care (attend a LTFU appointment) by T4 as measured by electronic health record (EHR) review. If attendance is not viewable in EHR, it will be ascertained by self-report (yes/no).

Conditions Studied

Interventions

  • BEHAVIORAL Stage 1 Written Information
  • BEHAVIORAL Stage 1 Low Touch Intervention
  • BEHAVIORAL Stage 2 Written Information
  • BEHAVIORAL Stage 2 Low Touch Intervention
  • BEHAVIORAL Stage 2 High Touch Intervention

Study Locations (3)

Pennsylvania

  • Children's Hospital of Philadelphia - Philadelphia
  • Penn Medicine - Philadelphia

Ohio

  • Nationwide Children's Hospital - Columbus

Trial Details

FieldValue
Enrollment Target 530 participants
Start Date 2025-08-01
Est. Completion 2028-04-30
Phase NA
Children's Hospital of Philadelphia

431 total trials

What NCT07138040 shows while recruiting

NCT07138040 is an interventional study that assigns participants to a tested intervention. The registered 530 participants enrollment target is mid-sized for trials with a published cap, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (85% lower).

The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 5 interventions - of which Stage 1 Written Information is the first listed.

NCT07138040 reports a single indexed study location in Pennsylvania, Ohio.

Frequently Asked Questions

What is clinical trial NCT07138040 about?

NCT07138040 is a clinical study titled "Re-Engaging AYA Survivors in Cancer-Related Healthcare". The goal of this clinical trial is to test the efficacy (how well they work) of different digital interventions that deliver information to adolescent and young adult (AYA) survivors of childhood cancer to promote re-engagement in cancer-related long-term follow-up care (LTFU). The main aims are: *...

What is the current status of trial NCT07138040?

This trial is currently recruiting. It is a NA study. The enrollment target is 530 participants. The study started on 2025-08-01. Estimated completion is 2028-04-30.

What conditions does trial NCT07138040 study?

This clinical trial studies the following conditions: Cancer.

What interventions are being tested in trial NCT07138040?

The interventions under investigation include: Stage 1 Written Information (BEHAVIORAL), Stage 1 Low Touch Intervention (BEHAVIORAL), Stage 2 Written Information (BEHAVIORAL), Stage 2 Low Touch Intervention (BEHAVIORAL), Stage 2 High Touch Intervention (BEHAVIORAL).

Who is sponsoring clinical trial NCT07138040?

This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07138040 being conducted?

This trial has 3 study locations across Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07138040's enrollment target sits among peer trials

530 116th of 615 higher than 500 of 615 other Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06646276 · 530 participants · Phase 3

    A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

  • NCT06703476 · 530 participants · Phase 3

    A Study of Surgical Techniques During Cystectomy

  • NCT06880744 · 530 participants · Phase 3

    A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

  • NCT07219173 · 531 participants · Phase 2

    A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07138040, the US trial registry maintained by the National Library of Medicine. NCT07138040 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.